The role of ER expression in these tumor entities, however, is less well defined compared to that in breast cancer, since ligand/ER interactions may be modified by affinity, transcriptional activation of genes, interaction with cofactors, heterogeneous receptor dimerization, ER splice variants and ERα/ERβ ratios [26]. The gene discussed is ESR2; the disease is neoplasm.